Skip to main content
35. survive
LeukemiaArticleYARN

Leukemia Survival Rate and Life Expectancy: What the Numbers Really Mean

Leukemia survival rate figures describe groups of people diagnosed years ago, not you. Here is how European survival differs by type and age, what the numbers can't tell you, and what to ask your hematologist.

Published:
Updated:

Key takeaways

  • A leukemia survival rate is a group average built from people diagnosed years ago. It describes a population, not the person reading it [1].
  • The main types behave like different diseases. In Europe, five-year survival for adults diagnosed in 2006 to 2008 was 69.0% for chronic lymphocytic leukemia (CLL) and 14.8% for acute myeloid leukemia (AML), not counting the subtype acute promyelocytic leukemia (APL) [2].
  • Age changes the picture. In a European study, an estimated 90% of children aged 1 to 4 diagnosed with acute lymphoblastic leukemia (ALL) in the early 2000s were cured, against 48% of people aged 20 to 24 [3].
  • The published statistics lag behind treatment. The latest European figures here cover people diagnosed up to 2013 [1], and a CAR T-cell therapy for ALL was authorized in the EU in 2018 [4].
  • The family question depends on the type: most people with CLL have no family history of it [5]. For other types, ask your hematologist.
  • Your own prognosis can come only from your hematologist, who has your full clinical picture.

If you're reading this a day or two after a leukemia diagnosis, I want to say something before we get to any numbers. Looking up a leukemia survival rate right now is one of the hardest things a person can do, especially while frightened and probably exhausted. That takes courage. So let's go slowly and be honest, because honesty is more useful to you than false comfort.

Let's start with what the European data show. In the EUROCARE-5 study, five-year relative survival for adults aged 15 and over with chronic myeloid leukemia (CML) rose from 32.3% for people diagnosed in 1997 to 1999 to 54.4% for those diagnosed in 2006 to 2008, while for AML (excluding APL) it moved only from 12.6% to 14.8% [2]. In the later EUROCARE-6 analysis of people aged 15 to 39, based on diagnoses from 2006 to 2013, five-year relative survival was about 60% for ALL and AML, 85% for APL and 93% for CML [1].

The two sets of figures differ because they come from two EUROCARE studies, which use data from population-based cancer registries across Europe and cover different ages and different years [1][2]. A survival rate is a statistic about a large group of strangers. It is not a prediction about you. Below you will find what these numbers measure, why they vary so much between types of leukemia, and why the figure you saw a minute ago may already be out of date.

What leukemia survival statistics actually tell you

Survival percentages are easy to read as a countdown. They aren't one, and leukemia isn't one disease either.

A survival statistic looks backward, not forward. It tells you how a large group of people who were diagnosed years ago went on to fare [1]. It can't account for who you are, how your particular leukemia behaves, or what treatment you'll receive next month, and European cancer registries don't systematically collect information on molecular features or treatments received [1].

What "five-year relative survival" really measures

A number you'll often see is the five-year relative survival rate. In plain terms, it compares how many patients are alive five years after diagnosis with how many you would expect to be alive in the general population of the same age, sex, place of residence and calendar year, which corrects for deaths from other causes [1].

"Five-year" is a measuring stick, not a deadline. In the European data on ALL, five-year survival was always slightly higher than the proportion estimated as cured, and a small excess risk of death persisted beyond five years for patients who remained at risk of late treatment effects, late relapses and second primary cancers [3].

Why today's numbers are already out of date

The European figures here come from people diagnosed between 1997 and 2008 [2] and between 2006 and 2013 [1], and the EUROCARE-6 authors list the relatively old diagnostic period among the limitations of their study [1]. Treatment has moved on since then. Kymriah, a CAR T-cell therapy for B-cell ALL, was authorized in the EU on 23 August 2018 [4], after the diagnoses behind these figures.

So when you see a leukemia survival rate, picture it with an asterisk: it reflects the past. Ask your hematologist how newer treatments change the picture for your type.

Five-year survival rates by leukemia type

If you take one idea from this article, make it this: there is no single leukemia survival rate worth memorizing. In the European data, five-year survival for adults ranged from 14.8% to 69.0% depending on the type [2], so lumping the types together hides more than it reveals. If you're not sure how leukemia relates to the other blood cancers, our guide on types of blood cancer walks through leukemia, lymphoma, myeloma and MDS.

This table compares five-year relative survival across Europe for adults aged 15 and over.

Leukemia type1997 to 19992006 to 2008Worth knowing
Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)66.1%69.0%Tends to develop very slowly, and not everyone needs treatment straight away [6]
Acute promyelocytic leukemia (APL)50.1%61.9%Reported separately from other AML. Five-year survival was 85% in people aged 15 to 39 [1]
Chronic myeloid leukemia (CML)32.3%54.4%The biggest rise of the five groups. First-line treatment is a tyrosine kinase inhibitor (TKI) [7]
Precursor lymphoblastic leukemia / lymphoma (includes ALL)29.8%41.1%Combines leukemia and lymphoma. For ALL, survival differs a lot by age (see below) [3]
Acute myeloid leukemia (AML), excluding APL12.6%14.8%The lowest of the five groups. More common in older people [8]

Source: EUROCARE-5, 30 cancer registries in 20 European countries, age-standardized five-year relative survival [2]. The APL figures are not age-standardized.

Chronic lymphocytic leukemia (CLL)

CLL had the highest five-year survival of the five groups in the table [2]. Cancer Research UK adds that many people with CLL don't have any symptoms [6].

If you have very early stage CLL, you may not need treatment straight away [6]. Your hematologist may suggest "watch and wait", which Cancer Research UK describes as an option for some slow growing cancers that aren't causing symptoms, CLL among them [9]. It adds that for some slow growing cancers it is safe to delay treatment, and that having treatment straight away doesn't always mean you are more likely to be cured or to live longer [9]. If your hematologist suggests monitoring, it's a medical decision, not neglect.

Acute lymphoblastic leukemia (ALL)

ALL is the most common cancer in children aged 0 to 14 [3], and age splits the picture sharply. In a European study of young people diagnosed in the early 2000s, an estimated 90% of children aged 1 to 4 were cured, against 48% of those aged 20 to 24 [3].

The 41.1% in the table is for adults, covers lymphoblastic leukemia and lymphoma together, and measures survival rather than cure, so don't set it beside the cure figures above [2][3].

Chronic myeloid leukemia (CML)

CML is a good example of why old statistics mislead. The EUROCARE-6 authors note that CML survival has improved significantly since imatinib entered treatment at the beginning of the 2000s [1].

The 2020 recommendations of the European LeukemiaNet say that most patients with chronic phase CML now have a normal life expectancy, and that for some people with a lasting deep molecular response, stopping treatment may be considered, with the goal of treatment-free remission [7]. If a CML number you've seen feels grim, check how recent it is.

Acute myeloid leukemia (AML)

I'll be straight with you, because you deserve that. Among the groups in the table, AML (excluding APL) had the lowest five-year survival, 14.8% for adults diagnosed in 2006 to 2008 [2]. The NHS notes that AML can be diagnosed at any age but is more common in older people [8].

That single number hides a lot. APL, which the European studies report separately, stands apart: five-year survival was 85% for people aged 15 to 39 [1]. If you have AML, ask your hematologist how your age, your overall health and the genetic features of your leukemia cells shape your outlook.

Leukemia life expectancy by age group

If you've searched for "leukemia life expectancy" hoping for a personal timeline, I understand the impulse completely. But life expectancy here is another population statistic, not a countdown for any one person.

Age does shape the numbers. In EUROCARE-5, survival decreased with advancing age [2]. Among younger people, the EUROCARE-6 analysis found worse survival for those aged 15 to 39 than for children in all types of ALL and in AML, but better survival in CML [1]. The authors suggest possible explanations include differences between pediatric and adult treatment protocols, higher treatment toxicity in young adults, and lower participation in clinical trials compared with children [1].

The ALL data show the age pattern most clearly. This table gives the estimated proportion cured for people diagnosed in the early 2000s.

Age at diagnosisEstimated proportion cured
Under 1 year58%
1 to 4 years90%
5 to 9 years86%
10 to 14 years77%
15 to 19 years51%
20 to 24 years48%

Source: European study of ALL in people aged 0 to 24 [3]. In this study, cured means the patients' mortality is estimated to be the same as that of the rest of the population of the same age and sex.

If you're older, please don't read the average as your fate. The same word covers a child with ALL and an adult with AML, and a blended number serves neither of them well. Ask your hematologist how your age, fitness, other health conditions and goals shape your plan.

35.2 hope

Why leukemia survival rates have improved

It helps to know which direction the trend line points, especially on a hard day. In the European data it points up, and for some types it points up steeply [2]. For people aged 15 to 39, five-year relative survival rose by 11 percentage points for ALL, 8 for AML and 11 for CML between the 2004 to 2006 and 2010 to 2014 follow-up periods [1].

The EUROCARE-6 authors attribute the rise to better prognostication and risk-adapted therapy informed by a better understanding of the genetic alterations in these leukemias, increased use of targeted therapies, and better supportive care and salvage therapy [1]. The EUROCARE-5 authors write that widespread use of new and more effective treatment probably explains much of the increase [2].

One newer option is CAR T-cell therapy. Kymriah contains the patient's own T cells (a type of white blood cell), modified genetically to make a protein called CAR that can attach to a protein on cancer cells called CD19, and in the EU it is authorized for B-cell ALL in children and young adults up to 25 years of age whose cancer did not respond to previous treatment, has come back two or more times, or has come back after a stem cell transplant [4]. In its main study of 92 children and young adults, around 66% had a complete response in the 3 months after treatment, meaning no signs of the cancer were left, but serious side effects occur in most patients [4].

Is leukemia genetic or hereditary?

If you're typing "is leukemia genetic" or "is leukemia hereditary" into a search box, you may be thinking about your children, or about your own risk. Let's take it one piece at a time.

The difference between genetic and hereditary

The two words get used as if they mean the same thing. They don't. "Genetic" means to do with genes. "Hereditary" means passed down in a family. In leukemia, doctors look at genetic changes in the cancer cells to judge the outlook and choose treatment [1]. That is a different question from whether the disease runs in your family.

When family history does matter

Cancer Research UK looks at this for CLL. It says there is some kind of inherited genetic change in some people with CLL, but most people with CLL do not have a family history of it [5]. Your risk is higher if a close family member (a parent, sibling or child) has CLL, but most people with a family history of CLL do not develop it themselves [5].

For other types of leukemia, ask your hematologist whether family history matters in your case. If several close relatives have had blood cancers, mention it to your care team and ask whether genetic counseling makes sense for your family.

What shapes an individual's prognosis

Here is where you get some power back. A survival rate is fixed history, but some of what shapes your care is still in motion.

The European research points to the type of leukemia and the person's age [2], and to the genetic features of the leukemia cells, which doctors use to judge the outlook and choose treatment [1]. Where you are treated may matter too. EUROCARE-5 found that survival in eastern Europe was lower than in other regions, and its authors say the persistent differences across Europe suggest variations in the quality of care and in the availability of new treatments [2].

A later EUROCARE-6 analysis found that five-year and ten-year survival for AML was higher in countries in the highest quartile of national health expenditure than in the lowest quartile [10]. That is an association between countries, not proof of what would happen to you.

None of this tells you where to be treated. It is a reason to ask about clinical trials and second opinions.

✓ Do✗ Don't
Ask for your exact subtype and the genetic markers of your leukemiaApply a blended, all-types survival number to your own case
Ask whether a clinical trial fits your situationAssume older statistics reflect the treatments available now
Consider a second opinion at a specialist cancer centerTreat online forums as a substitute for your care team
Tell your team about any strong family history of blood cancerHide symptoms or worries to seem "easy" as a patient

Understanding late-stage blood cancer symptoms

Some of you arrived here after searching for "last stage of blood cancer symptoms" or "blood cancer stage 3", and I want to handle this gently, because that search can come from a frightened place.

First, a word about stages. For CLL, Cancer Research UK describes two staging systems: Binet, with stages A, B and C, and Rai, with stages 0 to 4 [11]. For CML, it says doctors use phases instead of stages, and the system decides whether there are two (chronic and blast) or three (chronic, accelerated and blast) [12]. So "blood cancer stage 3" doesn't describe one thing, and a "last stage" symptom list for one type may not fit another. Ask your hematologist how your own type is classified.

The NHS lists these as the main symptoms of acute myeloid leukemia [8]:

  • feeling very tired or weak
  • looking more pale than usual
  • shortness of breath
  • bleeding or bruising easily, or for no reason
  • getting ill a lot, or taking longer than usual to recover from illnesses
  • a high temperature
  • pain in the bones or joints
  • a swollen belly
  • swollen glands

But please don't map those symptoms onto yourself and conclude the worst. The NHS says these symptoms are very common and can be caused by many different conditions, and that having them does not definitely mean you have AML [8]. Only your own team, with your leukemia blood test results and other findings in front of them, can tell you where you actually stand.

If you're seeing symptoms that scare you, that's a phone call to your care team, not a verdict to face alone tonight. If you're caring for someone whose illness has advanced, ask their team what to expect and who to call at any hour.

Living with uncertainty

Nobody hands you a manual for the in-between. You are not cured and not in crisis; you are waiting, watching counts, living between scans. That uncertainty is its own kind of hard. If your feelings shift from day to day, our guide on the emotional stages of a cancer diagnosis explains what to expect.

Shrink the frame: instead of trying to predict the next five years, focus on the next decision, whether that's this cycle, this scan or this week. Lean on other people: give friends and family a concrete task, like a ride to chemo or a meal on Thursday. A support group can put you next to people going through something similar.

Stories can help too. Kyriakos was diagnosed with leukemia at 13, and in Kyriakos Stenos: Exploring the World and Living Fully he says humor has been a big part of his everyday life. Amelia was diagnosed with ALL at 4. In Amelia Deane: Crafting a Life Full of Color she says her family and anything creative, like art, music and movies, helped her through treatment. If it helps to see what life after treatment can look like, this guide to what being a cancer survivor means is a gentle place to start.

Try rationing the Googling. Reading survival statistics on a loop at midnight can deepen the groove of the fear. Set the phone down. The numbers will still be there tomorrow, when you're less alone with them.

35.3 survive

Questions to ask your hematologist about your prognosis

Internet statistics take you only so far. The bridge from a generic leukemia survival rate to your real outlook runs through your hematologist's office. Bring this list to your next appointment:

  • What is my exact subtype of leukemia?
  • What genetic or chromosomal features does my disease have, and what do they mean for my prognosis?
  • How do the published survival statistics apply, or not apply, to my situation specifically?
  • What will my response to the first round of treatment tell us?
  • Am I eligible for any clinical trials?
  • Would a second opinion be worth getting, and can you help arrange one?

Write the answers down, or bring someone who can. A 2003 review in the Journal of the Royal Society of Medicine reports that 40 to 80% of medical information provided by healthcare practitioners is forgotten immediately [13].

Frequently asked questions

Is leukemia curable?

It depends on the type and on age. In a European study of ALL, an estimated 90% of children aged 1 to 4 diagnosed in the early 2000s were cured, meaning their mortality is estimated to match that of the rest of the population of the same age and sex [3]. For chronic phase CML, European LeukemiaNet recommendations say most patients now have a normal life expectancy [7]. For other types, ask your hematologist what cure or long remission could mean for you.

Which type of leukemia is most serious?

In the European adult data, AML (excluding APL) had the lowest five-year survival of the groups reported, 14.8% for people diagnosed in 2006 to 2008, while APL, reported separately, had 61.9% [2].

Can you live a long life after leukemia?

For some people, yes. European LeukemiaNet recommendations say most patients with chronic phase CML now have a normal life expectancy [7]. Cancer Research UK says CLL tends to develop very slowly [6], and that some people on watch and wait never need any treatment [9].

How accurate are leukemia survival rates?

They describe groups, not individuals. Population-based estimates reflect the survival of all patients with a certain cancer in the population a registry covers, and European registries don't systematically collect molecular information or the treatments patients received [1]. They are also built on older diagnoses: the latest European figures in this article cover people diagnosed up to 2013 [1].

Is leukemia passed down in families?

For CLL, mostly not. Cancer Research UK says most people with CLL do not have a family history of it, though your risk is higher if a close relative has CLL [5]. For other types, ask your hematologist.

The number on the screen isn't your story

Remember where we started: you, frightened, looking up a leukemia survival rate in a hard week. The numbers are averages from the past. Your type, your age and your own test results will tell you more than any blended figure.

So here is your next step, and it's a small one. Put your questions on paper, take them to your hematologist, and let that conversation, with a real doctor who knows your real case, define your outlook. Not a statistic. Not a search result. A percentage describes a crowd. It was never going to describe you.

References

[1] Trama, A., Geerdes, E. E., Demuru, E., De Angelis, R., Karim-Kos, H. E., Troussard, X., Bennett, D., Marcos-Gragera, R., Kuehni, C. E., Liu, H., Bernasconi, A., Vener, C., Guevara, M., Zwaan, C. M., Mayer-da-Silva, A., Paapsi, K., Ragusa, R., Smith, O. P., & EUROCARE-6 Working Group. (2025). Survival of European children, adolescents and young adults diagnosed with haematological malignancies in the period 2000-2013: Results from EUROCARE-6, a population-based study. European Journal of Cancer, 222, Article 115336. https://doi.org/10.1016/j.ejca.2025.115336

[2] Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos-Gragera, R., Maynadié, M., Monnereau, A., Osca-Gelis, G., Visser, O., De Angelis, R., & EUROCARE-5 Working Group. (2014). Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study. The Lancet Oncology, 15(9), 931-942. https://doi.org/10.1016/S1470-2045(14)70282-7

[3] Gatta, G., Rossi, S., Foschi, R., Trama, A., Marcos-Gragera, R., Pastore, G., Peris-Bonet, R., Stiller, C., Capocaccia, R., & EUROCARE Working Group. (2013). Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002. Haematologica, 98(5), 744-752. https://doi.org/10.3324/haematol.2012.071597

[4] European Medicines Agency. (2026, September 1). Kymriah. Retrieved November 15, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah

[5] Cancer Research UK. (2024, August 30). Risks and causes of chronic lymphocytic leukaemia (CLL). Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/chronic-lymphocytic-leukaemia-cll/risks-causes

[6] Cancer Research UK. (2024, September 25). Chronic lymphocytic leukaemia (CLL). Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/chronic-lymphocytic-leukaemia-cll

[7] Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 34(4), 966-984. https://doi.org/10.1038/s41375-020-0776-2

[8] NHS. (2026, September 9). Symptoms of acute myeloid leukaemia. Retrieved November 15, 2026, from https://www.nhs.uk/conditions/acute-myeloid-leukaemia/symptoms/

[9] Cancer Research UK. (2024, July 18). Watch and wait. Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/treatment/watch-and-wait

[10] Vener, C., Lillini, R., De Angelis, R., Bonfarnuzzo, S., Poirel, H. A., Trama, A., Visser, O., Troussard, X., Marcos-Gragera, R., Maynadié, M., Demuru, E., Di Benedetto, C., Johannesen, T. B., Solans, M., Paapsi, K., Guevara, M., Mousavi, S. M., Blum, M., Von Moos, R., . . . EUROCARE-6 Working Group. (2025). Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based study. European Journal of Cancer, 220, Article 115231. https://doi.org/10.1016/j.ejca.2025.115231

[11] Cancer Research UK. (2024, September 6). Staging chronic lymphocytic leukaemia (CLL). Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/chronic-lymphocytic-leukaemia-cll/staging

[12] Cancer Research UK. (2025, June 12). Stages (phases) of chronic myeloid leukaemia (CML). Retrieved November 15, 2026, from https://cancerresearchuk.org/about-cancer/chronic-myeloid-leukaemia-cml/stages

[13] Kessels, R. P. C. (2003). Patients' memory for medical information. Journal of the Royal Society of Medicine, 96(5), 219-222. https://doi.org/10.1177/014107680309600504

This article provides informational support only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider for medical decisions.

YARN project logo

This content was created during the YARN project, co-funded under the EU4Health Programme in 2025-2028 (Grant Agreement No. 101219053).